Movement Disorders

Papers
(The H4-Index of Movement Disorders is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
John Michael Walshe (April 24, 1920–October 14, 2022)536
204
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism155
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia139
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters132
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?106
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia103
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy91
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?90
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [18F]‐FEMPA PET Study85
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease81
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease80
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 1278
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait76
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy74
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property69
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease66
May Infographic64
Movement Disorders: Volume 40, Number 6, June 202563
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating62
Movement Disorders: Volume 40, Number 2, February 202562
Issue Information62
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy61
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?61
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals61
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure60
In Memoriam Mahlon R. DeLong (1938–2024)60
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease57
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers57
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model56
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism55
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials54
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation54
Obituary for Jan O. Aasly (1950–2022)53
Author Index52
51
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and 18F‐Fluorodopa‐Positron Emission Tomography50
Thank you to Reviewers 202250
Downbeat Nystagmus in Episodic Ataxia Type 1 Associated with a Novel KCNA1 Mutation49
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation47
Diagnostic and Prognostic Value of External Anal SphincterEMGPatterns in Multiple System Atrophy46
Reply to: “Application of the mPSPRS to the Salerno Cohort”45
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease44
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease44
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy44
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity44
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease44
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease44
0.16139721870422